Table 2 Comparison of choice & dose of immunosuppression regimen and use of RAAS inhibitors between subjects with and without Post Transplant Erythrocytosis
Medication | ALL (n = 1123) | No PTE (n = 1048) | PTE (n = 75) | P-Value |
|---|---|---|---|---|
Induction Immunosuppression | ||||
 Anti-Thymocyte Globulin | 928 (83%) | 861 (82%) | 67 (89%) | 0.27 |
 Basiliximab | 163 (15%) | 154 (15%) | 9 (12%) | 0.72 |
 Alemtuzumab | 34 (3%) | 31 (3%) | 3 (4%) | 0.73 |
 Rituximab | 16 (1%) | 15 (1%) | 1 (1%) | 0.86 |
Maintenance Immunosuppression at Discharge | ||||
 Triple regimen with CNI, mycophenolate, and prednisone | 918 (82%) | 853 (81%) | 65 (87%) | 0.25 |
 Tacrolimus | 1075 (96%) | 1000 (96%) | 75 (100%) | 0.17 |
 Cyclosporine | 17 (2%) | 17 (2%) | 0 (0%) | 0.41 |
 Mycophenolate | 1086 (97%) | 1014 (97%) | 72 (96%) | 0.52 |
 Prednisone | 956 (85%) | 888 (85%) | 68 (91%) | 0.16 |
 Others (Sirolimus or Everolimus or Belatacept) | 6 (1%) | 6 (1%) | 0 (0%) | 0.51 |
Maintenance Immunosuppression at Follow-up up to 1 year | ||||
 Mycophenolate | 1048 (93%) | 979 (93%) | 69 (92%) | 0.63 |
 Average daily mycophenolate dose (mg) | 1185.9 (480.3) | 1184.5 (482.9) | 1205.9 (446.1) | 0.86 |
 Tacrolimus | 1075 (96%) | 1000 (95%) | 75 (100%) | 0.05 |
 Average daily tacrolimus dose (mg) | 8.0 (4.8) | 8.1 (4.9) | 6.6 (4.0) | 0.01 |
 Average daily tacrolimus dose (mg/kg) | 0.1 (0.07) | 0.11 (0.64) | 0.09 (0.06) | 0.03 |
 Cyclosporine | 42 (4%) | 42 (4%) | 0 (0%) | 0.07 |
 Prednisone | 953 (85%) | 886 (85%) | 67 (89%) | 0.26 |
Maintenance Immunosuppression at Follow-up up to 2 years | ||||
 Mycophenolate | 1058 (94%) | 988 (94%) | 70 (93%) | 0.73 |
 Average daily mycophenolate dose (mg) | 1145.78 (435.04) | 1143.26 (433.98) | 1181.31 (451.47) | 0.71 |
 Tacrolimus | 1078 (96%) | 1003 (96%) | 75 (100%) | 0.06 |
 Average daily tacrolimus dose (mg) | 8.12 (22.29) | 8.28 (3.09) | 6.04 (3.45) | 0.007 |
 Average daily tacrolimus dose (mg/kg) | 0.11 (0.28) | 0.11 (0.29) | 0.08 (0.05) | 0.01 |
 Cyclosporine | 49 (4%) | 48 (5%) | 1 (1%) | 0.18 |
 Prednisone | 963 (86%) | 894 (85%) | 69 (92%) | 0.10 |
Use of RAAS Inhibitors | ||||
 At 3 months | 62 (6%) | 57 (6%) | 5 (7%) | 0.62 |
 At 6 months | 90 (9%) | 80 (8%) | 10 (14%) | 0.11 |
 Anytime within 12 months | 182 (16%) | 164 (16%) | 18 (24%) | 0.05 |
 At 18 months | 171 (18%) | 154 (17%) | 17 (25%) | 0.11 |
 At 24 months | 181 (20%) | 162 (19%) | 19 (27%) | 0.05 |
 Anytime within 24 months | 257 (23%) | 231 (22%) | 26 (35%) | 0.01 |